FDA Approves First-Line Tx for Peripheral T-Cell Lymphoma

Share this content:
FDA Approves First-Line Tx for Peripheral T-Cell Lymphoma
FDA Approves First-Line Tx for Peripheral T-Cell Lymphoma

MONDAY, Nov. 19, 2018 (HealthDay News) -- The U.S. Food and Drug Administration on Friday expanded approval for the use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with specific types of peripheral T-cell lymphoma (PTCL).

The FDA stated in a press release that this approval is the first for treatment of newly diagnosed PTCL. Adcetris, a monoclonal antibody that binds to the CD30 protein, is now approved to treat previously untreated systemic anaplastic large cell lymphoma (ALCL) and other CD30-expressing PTCLs in combination with chemotherapy. In the past, the FDA approved Adcetris to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL), cHL after relapse, cHL after stem cell transplant when there is a high risk for relapse or progression, systemic ALCL after failure of other treatment, and primary cutaneous ALCL or CD30-expressing mycosis fungoides after failure of other treatment.

The new approval was based on a clinical trial of 453 patients with certain PTCLs. Patients received first-line treatment of Adcetris plus chemotherapy or standard chemotherapy. Researchers found that progression-free survival was significantly longer (hazard ratio, 0.71; P = 0.01) among patients who received Adcetris (median 48 months compared with 21 months).

The FDA noted the following common side effects with Adcetris plus chemotherapy: peripheral neuropathy, nausea and vomiting, diarrhea, low white blood cell counts, fatigue, mouth sores, constipation, hair loss, fever, and anemia. The FDA advises health care providers to monitor patients for infusion reactions, anaphylaxis, neuropathy, fever, gastrointestinal complications, infections, tumor lysis syndrome, serious skin reactions, pulmonary toxicity, and hepatotoxicity. The prescribing information includes a Boxed Warning advising of the risk for progressive multifocal leukoencephalopathy in patients receiving Adcetris.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

'Aggressive Steps' Needed to Stop Adolescent Use of E-Cigarettes

'Aggressive Steps' Needed to Stop Adolescent Use of ...

U.S. Surgeon General issues a call to action for parents, teachers, and health professionals

Exercise Linked to Reduced Mortality for Patients With Cancer

Exercise Linked to Reduced Mortality for Patients With ...

Mortality rate lower for habitually active patients and for those who started exercising after diagnosis

Hospitalizations Up for Homeless From 2007 to 2013

Hospitalizations Up for Homeless From 2007 to 2013

Homeless individuals hospitalized more often for mental illness, substance use disorder

is free, fast, and customized just for you!




Already a member?

Sign In Now »